GC
FLGT icon

Gratus Capital’s Fulgent Genetics FLGT Stock Holding History

Gratus Capital’s Portfolio FLGT Stock Details FLGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-10,000
Closed -$400K – 187
2020
Q3 		$400K Hold
10,000
– – 0.06% 130
2020
Q2 		$160K Hold
10,000
– – 0.03% 154
2020
Q1 		$108K Buy
+10,000
New +$139K 0.02% 162

Other funds holding FLGT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RJT
Raymond James Trust St. Petersburg, Florida $4.6B AUM 33.54% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NI
Nepsis Inc Minneapolis, Minnesota $295M AUM 35.44% 1-Year Est. Return

Gratus Capital's FLGT Position: Q4 2020 in Review

Gratus Capital sold out of Fulgent Genetics (FLGT) in Q4 2020, closing a stake of 10,000 shares — an estimated $400K sold.

Gratus Capital first reported a position in FLGT in Q1 2020 and held it in 3 quarters. The position peaked at $400K in Q3 2020. 196 funds tracked by Wall St. Rank hold FLGT as of Q4 2020.

  • Gratus Capital reported no remaining Fulgent Genetics position as of Q4 2020 after selling out during the quarter.
  • Gratus Capital sold 10,000 Fulgent Genetics shares in Q4 2020, an estimated $400K.
  • Gratus Capital first reported a position in Fulgent Genetics in Q1 2020 and held it in 3 quarters.
  • Gratus Capital's Fulgent Genetics position peaked at $400K in Q3 2020.
  • 196 funds tracked by Wall St. Rank held Fulgent Genetics as of Q4 2020.

Based on Gratus Capital's 13F filing for Q4 2020, filed 3 Feb 2021.